11,867 Shares of IDEXX Laboratories, Inc. $IDXX Bought by WoodTrust Financial Corp

WoodTrust Financial Corp bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 11,867 shares of the company’s stock, valued at approximately $6,197,000.

Several other hedge funds also recently made changes to their positions in the company. J. Stern & Co. LLP lifted its stake in IDEXX Laboratories by 23,694.7% during the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in IDEXX Laboratories during the second quarter valued at $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of IDEXX Laboratories by 4.6% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock worth $479,844,000 after purchasing an additional 39,700 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in shares of IDEXX Laboratories by 52.4% during the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after purchasing an additional 288,471 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of IDEXX Laboratories by 4.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock worth $322,145,000 after buying an additional 23,582 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX traded up $6.91 during mid-day trading on Friday, hitting $520.05. The stock had a trading volume of 148,573 shares, compared to its average volume of 568,005. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company has a 50 day simple moving average of $539.78 and a 200-day simple moving average of $553.31. The stock has a market capitalization of $40.97 billion, a price-to-earnings ratio of 36.56, a P/E/G ratio of 2.70 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping the consensus estimate of $3.94 by $0.33. The firm had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the transaction, the director directly owned 9,568 shares of the company’s stock, valued at $5,090,941.44. This represents a 18.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.79% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Citigroup lifted their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, August 27th. Barclays dropped their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Finally, UBS Group raised their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $747.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.